Kiacta Approval Status
- FDA approved: No
- Brand name: Kiacta
- Generic name: eprodisate
- Previous name: Fibrillex
- Company: Neurochem
- Treatment for: Amyloid A Amyloidosis
Kiacta (eprodisate) is an investigational glycosaminoglycan mimetic intended for use in the treatment of Amyloid A Amyloidosis.
In July 2007, Neurochem announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for Kiacta was approvable pending an additional efficacy trial.
Development Status and FDA Approval Process for Kiacta
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.